Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.0%

4 terminated/withdrawn out of 25 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

20%

5 trials in Phase 3/4

Results Transparency

11%

2 of 18 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

12(48.0%)

Phase 1

6(24.0%)

Phase 3

3(12.0%)

Phase 4

2(8.0%)

N/A

2(8.0%)

25Total

Phase 2(12)

Phase 1(6)

Phase 3(3)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT00113282Phase 2Completed

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

Role: collaborator

NCT00004978Phase 3Completed

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

Role: collaborator

NCT00110812Phase 2Completed

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People

Role: collaborator

NCT00061620Phase 1Completed

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

Role: collaborator

NCT00003126Phase 3Completed

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Role: collaborator

NCT00006441Not ApplicableCompleted

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

Role: collaborator

NCT00006864Phase 4Completed

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Role: collaborator

NCT00100906Phase 2Completed

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Role: collaborator

NCT00031564Phase 2Completed

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

Role: collaborator

NCT00616564Phase 2Completed

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Role: collaborator

NCT00120185Phase 2Completed

Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

Role: collaborator

NCT01270906Phase 1Terminated

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

Role: collaborator

NCT00149162Phase 3Unknown

Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2

Role: collaborator

NCT00250861Phase 2Terminated

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Role: collaborator

NCT00051688Phase 2Terminated

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

Role: lead

NCT00054873Phase 2Completed

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

Role: lead

NCT00045877Phase 2Completed

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

Role: lead

NCT00100737Phase 2Terminated

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Role: lead

NCT00045864Phase 2Completed

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Role: lead

NCT00262015Phase 4Unknown

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

Role: lead